Compare AGCO Corporation (AGCO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Merck & Co., Inc. — how do they compare? AGCO Corporation trades at $101.2 (market cap $7.10B), while Merck & Co., Inc. trades at $133.18 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 45.3× AGCO Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| AGCO | MRK | |
|---|---|---|
Market Cap | $7.10B | $321.77B |
Sector | Industrials | Health |
52-Week High | $140.49 | $131.84 |
52-Week Low | $100.14 | $77.60 |
Enterprise Value | $9.37B | $368.53B |
Dividend Yield | 1.18% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $101.58, up 0.7% today, but remains under pressure after a Q2 2026 earnings miss and lowered full-year guidance triggered an 11% sell-off in late July 2026. The stock shows bearish technical signals with support near $99 and resistance at $102. Fundamentally, 2025 revenue was $10.08B with a net income margin of 7.2%, but 2026 projections indicate softer profitability. Recent leadership changes and ongoing securities investigations add uncertainty, though the consensus price target of $124.63 suggests potential upside from current levels.
The outlook is cautious due to weaker agricultural demand and earnings volatility. Investment appeal hinges on execution of the PTx growth strategy and margin recovery, but risks include legal probes and cyclical industry headwinds. Analyst sentiment is mixed with 38% buy ratings, reflecting divided views on near-term recovery prospects.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
